Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gentisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 6/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.61 |
| ▸ | CA12 known ✓ | O43570 | 5/20 | 0.61 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.61 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL29395432 | 1.00 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29564483 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8084108 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL28741734 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1115092 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL7261031 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3981502 | 0.95 | CA12 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10984737 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL344388 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1457617 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057055-A | Formulations for radiation therapy and diagnostic imaging | 透明医药有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260069727-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | Clarity Pharmaceuticals Ltd (AU) | 2026-03-12 | — | — | US | claimed |
| EP-4572807-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | Clarity Pharmaceuticals Limited (AU) | 2025-06-25 | — | — | EP | claimed |
| EP-3587561-B1 | DEVICE AND METHOD FOR SEPARATING MOBILE CELLS | SELECTIVITY SAS (AR) | 2025-04-09 | — | — | EP | claimed |
| US-20250025584-A1 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | Point Biopharma, Inc. | 2025-01-23 | — | — | US | claimed |
| EP-4440627-A1 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | Point Biopharma, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118695876-A | Radiopharmaceutical treatment method and use | 普安生物制药有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-20240285816-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING | Clarity Pharmaceuticals Ltd (AU) | 2024-08-29 | — | — | US | claimed |
| CN-118331058-A | Advanced reinforcement learning-based intelligent sudden-defense maneuver decision-making method for hypersonic vehicle | 西北工业大学 | 2024-07-12 | — | — | CN | claimed |
| EP-4187017-B1 | FISH CABLEWAY | MONAI BERNHARD (AT) | 2024-05-01 | — | — | EP | claimed |
| EP-0359225-B1 | Reagents for the preparation of 5'-tagged oligonucleotides | DU PONT (US) | 1996-01-17 | — | — | EP | claimed |
| US-5262536-A | Fluorescent reagents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-11-16 | — | — | US | claimed |
| US-5026829-A | Complexed with technecium; in vitro stability; kit | UNIVERSITY OF CINCINNATI (US) | 1991-06-25 | — | — | US | claimed |
| US-4997928-A | DNA sequencing | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-05 | — | — | US | claimed |
| EP-0380016-A1 | Cyclo substituted propyleneamine oxime and its use as a brain imaging agent | UNIVERSITY OF CINCINNATI (US) | 1990-08-01 | — | — | EP | claimed |
| EP-0359225-A2 | Reagents for the preparation of 5'-tagged oligonucleotides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | claimed |
| US-4247534-A | TECHNETIUM AND METHANEHYDROXYDIPHOSPHONATE | THE PROCTER & GAMBLE COMPANY (US) | 1981-01-27 | — | — | US | claimed |
| US-4243652-A | Gastrointestinal scanning agent | THE PROCTER & GAMBLE COMPANY (US) | 1981-01-06 | — | — | US | claimed |
| US-4233284-A | GENESTIC ACID, SALT OR ESTER THEREOF IN COMBINATION WITH A PERTECHNETATE REDUCING AGENT BECOMES LOCALIZED IN SPECIFIC BODY ORGANS OR BONES | THE PROCTER & GAMBLE COMPANY (US) | 1980-11-11 | — | — | US | claimed |
| US-3943137-A | ANTITUMOR | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1976-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285816-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING | XPO5, XPOT, TP53 | CA1 3519/4885CA2 4662/4885CA12 204/4885 |
| US-20250025584-A1 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | FOLH1, KLK3, GNRHR | CA1 321/4885CA2 999/4885CA12 159/4885 |
| US-20260069727-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | GALR1, HCAR1, CA12 | CA1 64/4885CA2 280/4885CA12 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.